You are here: Industry Insights > mrsa

News List

ACURX PHARMACEUTICALS Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES firstwordpharma
June 30, 2021
Acurx announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares.
Nozin Can Help Mitigate Growing Risk of Hospital Bacterial Infections During COVID-19, Expert Suggests prnewswire
December 04, 2020
With recent COVID-19 spikes and rise in hospitalizations, 75 percent or more of hospital infection prevention efforts can be devoted to COVID-19.
The new polymer can kill drug-resistant bacteria worldpharmanews
December 17, 2019
Researchers from Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, and Nanyang Technological University (NTU) ...
Study warns of disinfectant use in hospitals pharmatimes
March 19, 2019
A new study has warned that the use of disinfectants to clean and control infections in hospitals should be regulated in the same way that prescribing antibiotics is.
Staph Infections Drop, but Levels Still Worry U.S. Health Officials drugs
March 06, 2019
Dangerous staph infections are declining in America, but they still pose a significant public health threat, a new report from the U.S. Centers for Disease Control and Prevention shows.
CDC: Invasive MRSA More Likely Among Injection Drug Users drugs
June 12, 2018
Injection drug users are more than 16-fold more likely to develop invasive methicillin-resistant Staphylococcus aureus (MRSA) infections, according to research published in the June 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidit
Treatment for MRSA no longer more costly than for susceptible Staph aureus infections europeanpharmaceuticalreview
May 15, 2018
A new study found that infections caused by the drug resistant bacteria – methicillin-resistant Staphylococcus aureus, known as MRSA – are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria.
Antibiotic from bacteria found on Kenyan ant could help beat MRSA europeanpharmaceuticalreview
June 27, 2017
A new antibiotic, produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant ‘superbugs’ like MRSA according to scientists.